BidaskClub upgraded shares of Innophos (NASDAQ:IPHS) from a strong sell rating to a sell rating in a research report report published on Friday morning.
Several other equities research analysts have also recently weighed in on the company. TheStreet cut Innophos from a b- rating to a c rating in a report on Wednesday, February 21st. Zacks Investment Research cut Innophos from a hold rating to a sell rating in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $51.00.
Get Innophos alerts:
Shares of Innophos stock opened at $46.60 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.70 and a current ratio of 3.22. The stock has a market cap of $910.59 million, a PE ratio of 18.79 and a beta of 0.78. Innophos has a 12 month low of $38.66 and a 12 month high of $51.34.
Innophos (NASDAQ:IPHS) last announced its quarterly earnings data on Tuesday, May 1st. The specialty chemicals company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.55 by $0.06. The firm had revenue of $205.00 million for the quarter, compared to analyst estimates of $196.91 million. Innophos had a return on equity of 14.26% and a net margin of 2.95%. The company’s revenue was up 23.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.59 EPS. research analysts forecast that Innophos will post 2.7 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 5th. Investors of record on Friday, May 18th will be issued a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a yield of 4.12%. The ex-dividend date is Thursday, May 17th. Innophos’s dividend payout ratio is presently 78.05%.
A number of hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC boosted its holdings in Innophos by 79.8% during the 1st quarter. Citadel Advisors LLC now owns 89,463 shares of the specialty chemicals company’s stock valued at $3,597,000 after acquiring an additional 39,718 shares during the period. Penn Capital Management Co. Inc. purchased a new stake in Innophos during the 1st quarter valued at about $3,307,000. Sei Investments Co. boosted its holdings in Innophos by 10.2% during the 1st quarter. Sei Investments Co. now owns 42,365 shares of the specialty chemicals company’s stock valued at $1,703,000 after acquiring an additional 3,918 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Innophos by 1.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,012,438 shares of the specialty chemicals company’s stock valued at $40,710,000 after acquiring an additional 17,808 shares during the period. Finally, Thomson Horstmann & Bryant Inc. boosted its holdings in Innophos by 8.4% during the 1st quarter. Thomson Horstmann & Bryant Inc. now owns 20,366 shares of the specialty chemicals company’s stock valued at $818,000 after acquiring an additional 1,570 shares during the period. Institutional investors own 97.20% of the company’s stock.
Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.